Rafferty Asset Management LLC Has $1.28 Million Stock Holdings in Intellia Therapeutics, Inc. $NTLA

Key Points

• Rafferty Asset Management LLC reduced its stake in Intellia Therapeutics by 29.4%, selling 75,112 shares, and now holds 180,092 shares valued at approximately $1.28 million.
• Several institutional investors have also made significant adjustments to their holdings in NTLA, with some increasing their stakes by over 800% during the first quarter.
• Intellia Therapeutics reported a 104.3% increase in revenue year-over-year, totaling $14.25 million, and exceeded earnings estimates with a loss of $0.99 per share, compared to analysts' expected loss of $1.03.

Rafferty Asset Management LLC decreased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 29.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 180,092 shares of the company's stock after selling 75,112 shares during the period. Rafferty Asset Management LLC owned about 0.17% of Intellia Therapeutics worth $1,280,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Intellia Therapeutics in the 4th quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. lifted its stake in Intellia Therapeutics by 56.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after acquiring an additional 1,655 shares in the last quarter. Harbour Investments Inc. lifted its stake in Intellia Therapeutics by 76.7% in the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock valued at $37,000 after acquiring an additional 2,264 shares in the last quarter. Quantbot Technologies LP lifted its stake in Intellia Therapeutics by 846.4% in the 1st quarter. Quantbot Technologies LP now owns 6,663 shares of the company's stock valued at $47,000 after acquiring an additional 5,959 shares in the last quarter. Finally, 49 Wealth Management LLC bought a new stake in Intellia Therapeutics in the 1st quarter valued at approximately $74,000. Institutional investors own 88.77% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on NTLA. Royal Bank Of Canada cut their target price on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company reiterated an "overweight" rating and set a $45.00 price objective (down previously from $50.00) on shares of Intellia Therapeutics in a research note on Friday, August 8th. Chardan Capital dropped their price objective on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wedbush reiterated a "neutral" rating and set a $7.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 16th. Finally, Guggenheim reiterated a "buy" rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, August 13th. Twelve equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Intellia Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $29.05.

Intellia Therapeutics Stock Down 0.8%

Shares of NTLA stock traded down $0.09 during trading on Thursday, reaching $11.62. 2,967,974 shares of the company's stock were exchanged, compared to its average volume of 4,080,202. The stock has a market capitalization of $1.25 billion, a PE ratio of -2.48 and a beta of 2.28. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.76. The firm's fifty day moving average price is $11.40 and its 200-day moving average price is $9.61.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.04. The firm had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company's revenue for the quarter was up 104.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.52) EPS. As a group, analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other news, Director William J. Chase bought 100,000 shares of the company's stock in a transaction on Wednesday, August 20th. The stock was purchased at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the transaction, the director owned 134,693 shares of the company's stock, valued at $1,350,970.79. This trade represents a 288.24% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the transaction, the executive vice president owned 106,062 shares of the company's stock, valued at $1,486,989.24. This represents a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,534 shares of company stock valued at $153,837. 3.10% of the stock is owned by corporate insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.